SCHEMBL24418445

SCHEMBL24418445

CCS(=O)(=O)N1CCN(c2ccc(-c3n[nH]c4cc(=O)n(-c5c(C)cccc5F)nc34)cn2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.38
NTRK1 P04629 7/20 0.37
KDR P35968 1/20 0.37
ETV6 P41212 1/20 0.37
PRMT5 O14744 1/20 0.37
TNKS O95271 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PLK4 O00444 1/20 0.35
FLT3 P36888 1/20 0.35
ACVR1 Q04771 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24418437 0.91 NTRK1 (0.40) LRRK2NTRK1TNKSKDM4EPLK4
SCHEMBL29606913 0.90 TNKS (0.46) KDRETV6TNKSPLK4FLT3
SCHEMBL24418315 0.90 TNKS (0.46) KDRETV6TNKSPLK4FLT3
SCHEMBL26501879 0.89 NTRK1 (0.37) NTRK1KDRETV6TNKSPLK4
SCHEMBL24418380 0.89 MAP4K1 (0.40) ALDH1A1MAPTMEN1LMNAPOLB
SCHEMBL30596043 0.89 MAP4K1 (0.40) ALDH1A1MAPTMEN1LMNAPOLB
SCHEMBL26351325 0.88 AURKA (0.44) NTRK1TNKSPLK4FLT3ACVR1
SCHEMBL24418646 0.88 TLR9 (0.41) LRRK2NTRK1TNKSPLK4FLT3
SCHEMBL24418379 0.87 WNT3A (0.42) LRRK2NTRK1KDRETV6TNKS
SCHEMBL24418443 0.86 JAK2 (0.38) LRRK2NTRK1TNKSPLK4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223759-B1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO LTD (CN) 2025-06-11 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US claimed
EP-4223759-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Broadenbio Co., Ltd. (CN) 2023-08-09 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US disclosed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US disclosed
WO-2022095904-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京伯汇生物技术有限公司 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PDXK, CMPK1, GCK LRRK2 3562/4885NTRK1 1243/4885KDR 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.